Apixaban for Prevention of Acute Ischemic and Safety Events - APPRAISE

Description:

The goal of the trial was to evaluate the impact of bleeding from various doses of apixaban, an oral direct factor Xa inhibitor, compared with placebo, in patients with a recent acute coronary syndrome (ACS).